Clinical Trial Update: Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease [Phase 4]

View source ↗

Summary

The Phase 4 open-label trial of fluoxetine for treating depression in patients with end-stage renal disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Fluoxetine (Fluoxetine)

Snippet

Sponsor: Creighton University | Conditions: Depression | Phase 4 | Status: WITHDRAWN